7/8/2020 8:14:51 AM
Corbus Pharma Appoints George Golumbeski To Board
7/8/2020 8:07:36 AM
Corbus Pharmaceuticals Appoints George Golumbeski To Board
6/22/2020 8:27:51 AM
Corbus Says Last Subject Completed Final Visit In Phase 2b JBT101-CF-002 Trial
6/1/2020 8:17:06 AM
Corbus Reports Baseline Patient Demographics & Disease Characteristics In Phase 2b Study Of Lenabasum In Cystic Fibrosis
5/27/2020 8:16:17 AM
Corbus Pharma Reports Last Subject Visit In RESOLVE-1 Phase 3 Study Of Lenabasum For Systemic Sclerosis
3/12/2020 7:26:20 AM
Corbus Pharma Q4 Net Loss $26.6 Mln Or $0.41/Shr Vs Loss Of $17.3 Mln Or $0.30/Shr Last Year
3/12/2020 7:13:28 AM
Corbus Q4 Net Loss $26.6 Mln Or $0.41 Per Share
3/10/2020 8:19:56 AM
Corbus Appoints Pete Salzmann To Its Board
3/4/2019 9:21:01 AM
Corbus Pharmaceuticals Appoints Craig Millian As Chief Commercial Officer
1/25/2019 9:04:03 AM
Corbus Pharmaceuticals Prices Public Offering Of 5.39 Mln Shares At $6.50/Shr
1/24/2019 4:04:56 PM
Corbus Pharmaceuticals Announces Proposed Public Offering Of Common Stock
1/3/2019 10:04:47 AM
Corbus Collaborates With Kaken To Develop Lenabasum In Japan For Systemic Sclerosis And Dermatomyositis
12/18/2018 8:52:02 AM
Corbus Announces Issuance Of Composition Of Matter Patent Related To Lenabasum
11/8/2018 7:20:32 AM
Corbus Pharma Q3 Net Loss $14.6 Mln Or $0.26/Shr Vs Loss $6.967 Mln Or $0.14/Shr Last Year
10/22/2018 8:25:29 AM
Corbus Pharma Presents Lenabasum Long-Term Open-Label Clinical Data
9/18/2018 8:06:42 AM
Corbus Receives Orphan Designation In EU To Lenabasum For Treatment Of Dermatomyositis
9/14/2018 8:07:46 AM
Corbus Pharma Announces Presentation Of Three Abstracts And New Lenabasum Data At 2018 ACR Annual Meeting
8/8/2018 9:18:06 AM
Corbus Q2 Net Loss $12.10 Mln Or $0.21 Per Share
7/25/2018 9:20:42 AM
Corbus /o Commence Phase 3 Study Of Lenabasum For The Treatment Of Rare Autoimmune Disease Dermatomyositis